What Is Martin Shkreli’s Net Worth? (Recent Reports)
|Net Worth||$8 Million|
|Born||March 17, 1983|
|Age||40 Years Old|
|Birth Place||Brooklyn, New York, United States of America|
|Source of Income||Executive, Hedge Fund Manager, and Biotech founder|
Martin Shkreli is a convicted felon and former American hedge fund manager. Shkreli’s net worth is expected to have dropped to $8 million as a result of his conviction.
His net worth was previously presumed to be approximately $70 million in 2023.
He is a co-founder of three hedge funds: Elea Capital, MSMB Capital Management, and MSMB Healthcare.
Shkreli co-founded and served as CEO of two pharmaceutical businesses: Retrophin and Turing Pharmaceuticals, now known as Vyera Pharmaceuticals.
Do you want to know more about him? If yes, keep reading!
Martin Shkreli Biography/Wikipedia/Wiki
|Real Name||Martin Shkreli|
|Known As||Martin Shkreli|
|Birth Date||March 17, 1983|
|Age||40 Years Old|
|Spouse / Girlfriend||Unknown|
|Net Worth||$8 Million|
|Profession||Executive, Hedge Fund Manager, and Biotech founder|
How Was Martin Shkreli’s Early Life And Education?
Martin Shkreli’s birthdate is March 17, 1983. He was born in Coney Island Hospital in the New York City borough of Brooklyn, America, to Albanian immigrant parents.
His parents emigrated to America and worked as janitors.
Shkreli, his two sisters, and his brother grew up in Sheepshead Bay, Brooklyn, in a working-class neighborhood. He was raised a Catholic and attended Sunday school as a child.
Shkreli attended Hunter College High School. He dropped out before his final year and finished his diploma requirements at City-As-School High School, an alternative learning high school.
He graduated from Baruch College with a bachelor’s degree in business administration in 2004.
When he was 17, he was accepted into a program that landed him an internship with the Wall Street hedge fund Cramer Berkowitz and Company.
How Did Martin Shkreli Start His Career?
Shkreli suggested shorting the stock of Regeneron, a biotech company developing a weight-loss medicine, while at Cramer Berkowitz and Company. Cramer gained when the price of Regeneron fell as predicted by Shkreli.
The SEC took notice and wanted to investigate how Shkreli could have predicted it, but there were no indications that he had any insider knowledge or had participated in any crime.
He left Cramer Berkowitz after four years as an intern and associate to work as a financial analyst at two prominent investment banks.
Shkreli founded Retrophin in 2011 to make additional biotech investments. He was fired by Retrophin’s board of directors in the fall of 2014.
Retrophin filed a $65 million lawsuit against him, alleging that he engaged in stock trading irregularities and other violations of securities rules.
He started yet another company, Turing Pharmaceuticals, in February 2015.
He captured the public’s attention in 2015 when Shkreli purchased the lifesaving HIV medicine Daraprim and then hiked the price of the drug from $13.50 per pill to $750 – which was a more than 5,000% rise.
The price increase instantly established him as both a villain and a punchline, earning him the disparaging moniker “Pharma Bro.”
Daraprim, according to the suit, was readily available and reasonably priced until it was purchased by Shkreli’s firm in 2015. He actively sought to block other companies from bringing a generic version of this medicine to market.
Turing declared in November 2015 that the business would not cut the list price of Daraprim. Instead, Shkreli engaged lobbyists and a crisis PR agency to justify the price increase.
Humanigen, a biotech company Shkreli briefly headed, saw its stock rise 30% in June 2020 as a consequence of the first human study of its investigational coronavirus treatment.
Martin Shkreli’s Personal Life
Shkreli was reported to be in a relationship with Christie Smythe, a former Bloomberg News reporter who broke the story of his arrest in 2015. Their partnership was termed as “life partners” by Smythe.
Smythe revealed in October 2021 that the two had broken up but remained friends.
How Does Martin Shkreli Make His Money?
The major sources of income through which Shkreli makes his money are:
- Earning as a Hedge Fund Manager
- Earning as a Founder of Biotech companies
Martin Shkreli’s Social Media Accounts
Major Career Highlights
- Shkreli founded Retrophin in 2011.
- He is a co-founder of MSMB Capital Management, MSMB Healthcare, and Elea Capital.
- He is the former CEO of Gödel Systems.
- He has been labeled the “Pharma Bro” and the “Most Hated Man in America” for “scheming to dominate the market” on Daraprim.
Martin Shkreli Quotes
“Invariably, when people read the headline about Martin Shkreli, they hate Martin Shkreli. When they get to know Martin Shkreli, they love Martin Shkreli.”Martin Shkreli
“Politics are well past logic. It’s entertainment.”Martin Shkreli
“My shareholders expect me to make the most profit. That’s the ugly, dirty truth”Martin Shkreli
Lessons From Martin Shkreli’s Life
- Be compassionate.
- Be honest and sincere.
Martin Shkreli is a co-founder of Elea Capital, MSMB Capital Management, and MSMB Healthcare.
He is also the former CEO of Gödel Systems. He’s been labeled the “Pharma Bro” and the “Most Hated Man in America” for “scheming to dominate the market” on Daraprim.
As per recent updates, the net worth of Martin Shkreli is $8 million…!
- Michael Sonnenshein Net Worth
- Joonatan Lintala Net Worth
- Dan Morehead Net Worth
- Barry Silbert Net Worth
- Mike Novogratz Net Worth
- Fred Ehrsam Net Worth
Frequently Asked Questions
These are the questions asked about Shkreli:
What Is Martin Shkreli’s Height?
Martin Shkreli is 5’ 7” tall.
What Is Martin Shkreli’s Age?
Martin Shkreli is 40 years old.
When Was Martin Shkreli Released From Prison?
Martin Shkreli was released on May 18, 2022.
Is Martin Shkreli Married?
No, Martin Shkreli is reportedly single.
Where Did Martin Shkreli Study?
Martin Shkreli graduated from Baruch College with a bachelor’s degree in business administration.
PS: This is not the net worth of Shkreli. The data given here has been collected from various sources and may vary with time.